IP Library › Granted Patent US 12,391,736
Granted Patent B2
US 12,391,736 · App. 17/262,917 · Granted Aug 19, 2025

Off-the-shelf cancer vaccines

Inventor: Ronald Hans Anton Plasterk (Amsterdam, NL)
Assignee: CureVac Netherlands B.V.
C07K14/4748A61K39/0011A61K39/001151C07K5/0808C07K7/08C12Q1/6886A61K39/00A61K2039/645C07K2319/00C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,736
App. No.
17/262,917
Granted
Aug 19, 2025
Kind
B2
Abstract

The present invention relates generally to peptide comprising two or more tumor specific neo open-reading-frame peptides (NOPs), and isolated nucleic acids encoding such peptides, and the uses of these peptides and/or isolated nucleic acids to produce cancer vaccines and the like. With the present invention it becomes possible to provide off-the-shelf cancer vaccines and the like within a short period of time and for potentially 30% of the total population of patients suffering from cancer.

Claims (3)

1. A peptide comprising at least two amino acid sequences, wherein each of said at least two amino acid sequences is independently selected from the group consisting of SEQ ID NOS: 601 to 605, or an isolated nucleic acid comprising a nucleotide sequence encoding said peptide.

2. The peptide or isolated nucleic acid according to claim 1 , wherein one of said at least two amino acid sequences is SEQ ID NO: 602, or a nucleic acid sequence encoding said peptide, and another of said at least two amino acid sequences is selected from the group consisting of SEQ ID NOS: 601, 603, 604, and 605, or an isolated nucleic acid comprising a nucleotide sequence encoding said peptide.

3. The peptide or isolated nucleic acid according to claim 2 , wherein said at least two amino acid sequences comprise SEQ ID NO:602 and SEQ ID NO:601, or isolated nucleic acid sequences encoding said peptides.

Assignments (2)
CHANGE OF NAME Recorded Jul 20, 2022
From: FRAME PHARMACEUTICALS B.V.
To: CUREVAC NETHERLANDS B.V.
Reel/Frame 060756/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2021
From: PLASTERK, RONALD HANS ANTON
To: FRAME PHARMACEUTICALS B.V.
Reel/Frame 055226/0460 →
Priority Claims (2)
NL 2021400 · Jul 26, 2018 · national
NL 2022447 · Jan 24, 2019 · national
Continuity (1)
Related Publication 20210238244A1 · Aug 5, 2021
References Cited (79)
US 9115390B2 · Liss et al. · 2015 [cited by applicant]
US 20050112134A1 · Graddis et al. · 2005 [cited by applicant]
US 20070083334A1 · Mintz et al. · 2007 [cited by applicant]
US 20160069895A1 · Delamarre et al. · 2016 [cited by applicant]
US 20160101170A1 · Hacohen et al. · 2016 [cited by applicant]
US 20170028043A1 · Benz et al. · 2017 [cited by applicant]
US 20170028044A1 · Soon-Shiong et al. · 2017 [cited by applicant]
US 20170032082A1 · Nguyen et al. · 2017 [cited by applicant]
US 20170032103A1 · Nguyen et al. · 2017 [cited by applicant]
US 20170202939A1 · Carreno et al. · 2017 [cited by applicant]
US 20170312351A1 · Niazi et al. · 2017 [cited by applicant]
US 20180064793A1 · Mcgranahan et al. · 2018 [cited by applicant]
US 20180078624A1 · Zhou et al. · 2018 [cited by applicant]
US 20180078625A1 · Moon et al. · 2018 [cited by applicant]
US 20180318409A1 · Valiante et al. · 2018 [cited by applicant]
US 20180340944A1 · Han et al. · 2018 [cited by applicant]
US 20190022202A1 · Granum et al. · 2019 [cited by applicant]
US 20190030147A1 · Artomov et al. · 2019 [cited by applicant]
US 20190060428A1 · Fritsch · 2019 [cited by applicant]
US 20190083593A1 · Sahin et al. · 2019 [cited by applicant]
US 20190091316A1 · Soon-Shiong et al. · 2019 [cited by applicant]
EP 2071334A1 · 2009 [cited by examiner]
WO 1995032731A2 · 1995 [cited by applicant]
WO 20040111075A2 · 2004 [cited by applicant]
WO 2007101227A8 · 2007 [cited by applicant]
WO 2011143656A2 · 2011 [cited by applicant]
WO 2012159754A2 · 2012 [cited by applicant]
WO 2014168874A2 · 2014 [cited by applicant]
WO 2015095811A2 · 2015 [cited by applicant]
WO 2016040900A1 · 2016 [cited by applicant]
WO 2016154544A1 · 2016 [cited by applicant]
WO 2016172722A1 · 2016 [cited by applicant]
WO 2016187508A2 · 2016 [cited by applicant]
WO 2016201049A2 · 2016 [cited by applicant]
WO 2017020026A1 · 2017 [cited by applicant]
WO 2017106638A1 · 2017 [cited by applicant]
WO 2017118702A1 · 2017 [cited by applicant]
WO 2017132547A1 · 2017 [cited by applicant]
WO 2017139694A1 · 2017 [cited by applicant]
WO 2017173321A1 · 2017 [cited by applicant]
WO 2017177207A1 · 2017 [cited by applicant]
WO 2017194170A1 · 2017 [cited by applicant]
WO 2017223085A2 · 2017 [cited by applicant]
WO 2018015433A2 · 2018 [cited by applicant]
WO 2018026896A1 · 2018 [cited by applicant]
WO 2018102584A1 · 2018 [cited by applicant]
WO 2018136664A1 · 2018 [cited by applicant]
WO 2018144082A1 · 2018 [cited by applicant]
WO 2018144775A1 · 2018 [cited by applicant]
WO 2018195357A1 · 2018 [cited by applicant]
WO 2018200389A1 · 2018 [cited by applicant]
WO 2018213803A1 · 2018 [cited by applicant]
WO 2018223092A1 · 2018 [cited by applicant]
WO 2018223094A1 · 2018 [cited by applicant]
WO 2018224405A1 · 2018 [cited by applicant]
WO 2018234506A2 · 2018 [cited by applicant]
WO 2018234516A2 · 2018 [cited by applicant]
WO 2019008364A1 · 2019 [cited by applicant]
WO 2019008365A1 · 2019 [cited by applicant]
WO WO2019012082A1 · 2019 [cited by examiner]
WO 2019036043A2 · 2019 [cited by applicant]
NLM, “ [cited by examiner]
Rajasagi, M. et al., “Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia”, Blood, 2014; 124(3):453-462; ISSN 0006-4971. [cited by applicant]
Roudko, V. et al., “Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors”, bioRxiv 2019; doi: https://doi.org/10.1101/662262; pp. 1-53. [cited by applicant]
Luhui, S. et al., “Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine.”, American Association for Cancer Research; vol. 73, No. 8, Suppl. 1, Apr. 2013 (Apr. 1, 2013). [cited by applicant]
Schwitalle, Y. et al., “Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells”, Cancer Immun. 2004 Academy of Cancer Immunology, CH-ISSN 1424-9734, vol. 4, Nr:1, pp. 1-10. [cited by applicant]
Koster, J. et al., “A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients”, Scientific Reports, 2019, vol. 9, Nr: 1. [cited by applicant]
Zhang, J. et al., “Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening”, Scientific Reports, vol. 8, No. 1, (2018), pp. 1-10. [cited by applicant]
Batista, M. T. et al., “Abstract 1463: FAST vaccines based on frameshift neoantigens may have advantages over personal vaccines”, Proceedings of American Association for Cancer Research Annual Meeting 2019, Mar. 29, 201… [cited by applicant]
Orfanelli, T. et al., “Shared tumor antigens in uterine cancers with microsatellite instability: Putative targets for immunotherapeutic approaches”, Gynecologic Oncology, Jun. 2019, 154(1):91, DOI: 10.1016/j.ygyno.2019.… [cited by applicant]
Linnebacher et al., “Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens”, Int. J. Cancer: 93, pp. 6-11 (2001). [cited by applicant]
Schumacher et al., “Neoantigens in cancer immunotherapy”, Science, 2015, vol. 348, Issue 6230, pp. 69-74. [cited by applicant]
Rahma et al., “A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma”, Journal of Translational Medicine, 2010, 8:8, 9 pages. [cited by applicant]
Hacohen et al., “Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines”, Cancer Immunol. Res., Jul. 2013; 1(1): 11-15, pp. 1-8. [cited by applicant]
Ito et al., “Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy”, J Clin Cell Immunol 2015, 6:2, pp. 1-7. [cited by applicant]
Tomczak et al., “The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge”, Contemp Oncol (Pozn). 2015, 19 (1A): A68-A77. [cited by applicant]
The Cancer Genome Atlas Research Network. “Comprehensive molecular characterization of clear cell renal cell carcinoma”, Nature (2013), 499, pp. 43-49. [cited by applicant]
Pavlopoulou et al., “Human cancer databases (review)”, Oncology Reports, 33: pp. 3-18, 2015. [cited by applicant]
Rammensee, H-G et al., “Cancer Vaccines: Some Basic Considerations”, Genomic and Personalized Medicine, 2009, Elsevier, pp. 573-589. [cited by applicant]